Literature DB >> 31502656

Alendronate effect in esophagus, stomach and liver: an animal based pathological study.

Theodora Papamitsou1, Sotiris Sotiriou2, Apostolos Papakoulas2, Alexandros Toskas2, Dimitrios Kamperis2, Sofia Karachrysafi2, Eva-Maria Dietrich2, Stergios Lialiaris3, Antonia Sioga2.   

Abstract

Bisphosphonates are commonly used in clinical practice. Their effectiveness is indisputable, however their adverse effects, especially in the GI tract, are still controversial. In our report, we demonstrate pathological findings of the effect of systematic alendronate administration in esophagus, stomach and the liver of an in-vivo animal model of 15 Wistar rats. Light microscopy with immunohistochemistry and electron microscopy were used. Microscopic findings of inflammation of the stomach and mild hepatic dysfunction were observed. Conclusively, alendronate can potentially affect gastric mucosa and liver function on this animal experimental model.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31502656     DOI: 10.14670/HH-18-161

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  29 in total

1.  [Severe acute hepatitis induced by alendronate].

Authors:  Christophe Carrère; Jean-Luc Duval; Bruno Godard; Jean-Pierre De Jaureguiberry; Jean-Marc Ciribilli
Journal:  Gastroenterol Clin Biol       Date:  2002-02

2.  A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation.

Authors:  P Argani; A Hawkins; C A Griffin; J D Goldstein; M Haas; J B Beckwith; C B Mankinen; E J Perlman
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 3.  Pharmacology of bisphosphonates.

Authors:  Serge Cremers; Socrates Papapoulos
Journal:  Bone       Date:  2011-01-31       Impact factor: 4.398

4.  Nonclinical model for assessing gastric effects of bisphosphonates.

Authors:  M A Blank; B L Ems; G W Gibson; W R Myers; S K Berman; R J Phipps; P N Smith
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

Review 5.  Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?

Authors:  Byron Cryer; Douglas C Bauer
Journal:  Mayo Clin Proc       Date:  2002-10       Impact factor: 7.616

6.  Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.

Authors:  D C Bauer; D Black; K Ensrud; D Thompson; M Hochberg; M Nevitt; T Musliner; D Freedholm
Journal:  Arch Intern Med       Date:  2000-02-28

Review 7.  Peptidyl hormones of endocrine cells origin in the gut--their discovery and physiological relevance.

Authors:  P Ceranowicz; Z Warzecha; A Dembinski
Journal:  J Physiol Pharmacol       Date:  2015-02       Impact factor: 3.011

8.  Role of soluble guanylate cyclase activation in the gastroprotective effect of the HO-1/CO pathway against alendronate-induced gastric damage in rats.

Authors:  Natália R D Costa; Renan O Silva; Lucas A D Nicolau; Larisse T Lucetti; Ana Paula M Santana; Karoline S Aragão; Pedro M G Soares; Ronaldo A Ribeiro; Marcellus H L P Souza; André L R Barbosa; Jand-Venes R Medeiros
Journal:  Eur J Pharmacol       Date:  2012-12-21       Impact factor: 4.432

Review 9.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

10.  Physiological and morphological effects of alendronate on rabbit esophageal epithelium.

Authors:  A Dobrucali; N A Tobey; M S Awayda; C Argote; S Abdulnour-Nakhoul; W Shao; R C Orlando
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-09       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.